HCV疫苗临床试验的研究进展  

Advance in research on clinical trials of hepatitis C virus vaccine

作　　者：高婷婷[1] 秦照玲[1] 戚中田[1] 

机构地区：[1]第二军医大学微生物学教研室全军生物侦检与防护重点实验室上海市医学生物防护重点实验室,上海200433

出　　处：《中国生物制品学杂志》2014年第7期964-967,共4页Chinese Journal of Biologicals

摘　　要：丙型肝炎病毒(hepatitis C virus,HCV)感染可引起慢性肝炎,最终导致肝衰竭、肝硬化和肝癌。目前尚无有效的HCV疫苗,其治疗仍以标准化方案聚乙二醇干扰素联合利巴韦林为主。其疗程长,费用高,副作用大,且不能从根本上解决慢性尤其是难治性丙肝的治疗难题,因此,HCV疫苗的研究迫在眉睫。本文就HCV疫苗临床试验的研究进展作一综述。Hepatitis C virus（HCV）infection is an important cause of chronic hepatitis,which eventually results in liver failure,cirrhosis or hepatocellular carcinoma. To date,there is no effective vaccine available against HCV. The standardof-care therapy for HCV infection involves a combination of pegylated interferon α and ribavirin. With long course,high cost and obvious side effect,the therapy cannot overcome the problem in treatment of chronic especially refractory hepatitis C,thus it is urgent to develop effective HCV vaccines. This paper reviews the advance in research on clinical trials of HCV vaccine.

关 键 词：丙型肝炎病毒 疫苗 临床试验 

分 类 号：R373.21[医药卫生—病原生物学] R392-33[医药卫生—基础医学]